Literature DB >> 19695765

A validation study of new risk grouping criteria for postoperative treatment in stage IB cervical cancers without high-risk factors: rethinking the Gynecologic Oncology Group criteria.

Suk-Joon Chang1, Woo Young Kim, Seung-Chul Yoo, Jong-Hyuck Yoon, Mison Chun, Ki-Hong Chang, Hee-Sug Ryu.   

Abstract

OBJECTIVE: The aim of this study was to verify whether the Gynecologic Oncology Group (GOG) criteria are valid in a different cohort of patients and to investigate simplified new criteria tailoring adjuvant radiation therapy in patients with intermediate-risk factors after radical hysterectomy. STUDY
DESIGN: We analyzed the data of 332 patients with FIGO stage IB cervical cancer who underwent radical hysterectomy between 1994 and 2007. Two hundred and twenty-five patients without high-risk factors (lymph node metastasis, parametrial invasion, or positive surgical margins) were identified and were classified into low-risk and high-risk groups according to the GOG criteria and new criteria based on combinations of intermediate-risk factors (large tumor size, deep stromal invasion, lymph-vascular space invasion). We evaluated the prognostic significance of both criteria.
RESULTS: We identified 140 low-risk patients and 85 high-risk patients in the application of the GOG criteria. Low-risk patients had significantly better disease-free survival (DFS) (P=0.001) and overall survival (OS) (P=0.013) than high-risk patients. There were 145 low-risk patients and 80 high-risk patients on applying the new criteria. Low-risk patients had significantly better DFS (P=0.001) and OS (P=0.013) than high-risk patients. The receiver operating characteristic (ROC) curves showed that both criteria had similar performance for predicting which patients would have help from adjuvant therapy.
CONCLUSION: This study demonstrated that the GOG criteria were still valid in the different population, the simplified new criteria were convenient to apply in practice, and the performance of the new criteria was as good as the GOGs.

Entities:  

Mesh:

Year:  2009        PMID: 19695765     DOI: 10.1016/j.ejogrb.2009.07.013

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  3 in total

1.  Cost-utility analysis of treatments for stage IB cervical cancer.

Authors:  Kanyarat Katanyoo; Naiyana Praditsitthikorn; Siriwan Tangjitgamol; Sumonmal Manusirivithaya; Busaba Supawattanabodee
Journal:  J Gynecol Oncol       Date:  2014-04-09       Impact factor: 4.401

2.  Preoperative SCC-Ag as a predictive marker for the use of adjuvant chemotherapy in cervical squamous cell carcinoma with intermediate-risk factors.

Authors:  Hong-Tao Guo; Xue-Han Bi; Ting Lei; Xiao Lv; Guang Yao; Yao Chen; Chang Liu
Journal:  BMC Cancer       Date:  2020-05-19       Impact factor: 4.430

3.  Preoperative Prediction of Lymphovascular Space Invasion in Cervical Cancer With Radiomics -Based Nomogram.

Authors:  Wei Du; Yu Wang; Dongdong Li; Xueming Xia; Qiaoyue Tan; Xiaoming Xiong; Zhiping Li
Journal:  Front Oncol       Date:  2021-07-12       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.